Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
allo-APZ2-CVU in chronic venous leg ulcers
NCT06489028Phase 3Active, not recruiting
- Sponsor
- RHEACELL
- Start
- Dec 2024
- Primary completion
- Apr 2027
- Modality
- Stem Cell Therapies
- Countries
- 12
01
Overview
A Phase 3 trial of EBESANAR in venous leg ulcer (VLU), sponsored by RHEACELL. Started Dec 2024; status: active, not recruiting.
02
Drugs
EBESANAR
03
Conditions
venous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT06489028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06489028.